Business / Finance

RSS

diaDexus fourth quarter total revenues increase 48% to $4.9 million

diaDexus, Inc.a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced financial results for the 2011 fourth quarter and year-end.

16 Mar 2012

American Shared Hospital Services fourth quarter revenues increase 8.4% to $4,500,000

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the fourth quarter and 2011.

From Elekta 15 Mar 2012

Zynex 2011 net revenue increases 42% to $34,148,000

15 Mar 2012

Shire enters agreement to acquire FerroKin BioSciences

Shire plc, the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.

15 Mar 2012

GenMark Diagnostics fourth quarter revenues increase to $2.0 million

GenMark Diagnostics, Inc. today reported additional financial information for the fourth quarter ended December 31, 2011 that was unavailable at the time it released preliminary financial results on March 8, 2012.

15 Mar 2012

GenVec 2011 net loss decreases to $7.4 million

Today GenVec, Inc. announced financial results for the fourth quarter and year ended December 31, 2011. For the year ended December 31, 2011, the Company reported a net loss of $7.4 million, or $0.58 per share, compared with a net loss of $12.3 million, or $0.97 per share, for the year ended December 31, 2010.

15 Mar 2012

China Pharma revenue increases 9% to $81.2M for full year 2011

China Pharma Holdings, Inc., a fully-integrated specialty pharmaceuticals company in China, today announced financial results for the year ended December 31, 2011.

15 Mar 2012

MDxHealth fourth quarter total revenues increase 48% to €0.9M

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced results for Q4 and full year 2011.

15 Mar 2012

Insmed fourth quarter revenues increase to $1.4 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the fourth quarter and fiscal year ended December 31, 2011.

13 Mar 2012

Amilpar fourth quarter operating revenues increase 22.5% to R$ 2,521.1M

Amil Participacoes S.A., the largest healthcare operator in Brazil, announces today its consolidated results for December 31, 2011, in accordance with Brazilian corporate law and the ANS account chart.

13 Mar 2012

Masimo announces acquisition of Spire Semiconductor

Masimo, the inventor of Masimo Rainbow Pulse CO-Oximetry, Masimo Rainbow Acoustic Monitoring, and Masimo SET Measure-Through Motion and Low Perfusion pulse oximetry, today announced it has acquired substantially all of the assets of Spire Semiconductor, LLC, maker of advanced light emitting diode and other advanced component-level technologies.

12 Mar 2012

HemaQuest closes $13 million extension of Series B financing

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has closed a $13 million extension of their Series B financing.

12 Mar 2012

ACRONET joins Medidata Partner Program

As clinical trial activity in the Asia Pacific region continues to expand and contract research organizations (CRO) increasingly provide sponsors with a range of strategic services and support, ACRONET joined the Medidata Partner Program to enhance its technology offerings across the clinical development process.

12 Mar 2012

OPKO Health, Scripps Research partner to commercialize Parkinson's disease compound, SR 3306

The Scripps Research Institute and OPKO Health, Inc. today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinson's disease.

12 Mar 2012

Medisafe 1 Technologies, Natural Dream Laboratories enter distribution agreement

Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has signed a distribution agreement with Natural Dream Laboratories Company Ltd for Medisafe 1 to carry a wide range of health related products in the Natural Dream laboratories Company product line.

12 Mar 2012

LensAR closes $24 million private financing

LensAR Inc., a developer of the next generation of laser systems for cataract surgery, announced the closing of a $24 million private financing which included investments from Aisling Capital and Florida Growth Fund (FGF).

12 Mar 2012

AB SCIEX announces commercial expansion in Brazil

AB SCIEX, a global leader in life science analytical technologies, today announced its expansion of commercial operations in Brazil to support the Brazilian scientific community's increasing use of mass spectrometry for food safety testing, environmental analysis, academic research, drug development, forensic toxicology and clinical research.

12 Mar 2012

Zynex announces acquisition of NeuroDyne Medical

Zynex, Inc., a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced the acquisition of substantially all the assets of NeuroDyne Medical, Corp., through its subsidiary Zynex NeuroDiagnostics, Inc., with an effective date of March 9, 2012.

12 Mar 2012

Antares Pharma fourth quarter revenues increase 65% to $5.4 million

Antares Pharma, Inc. today reported financial and operating results for the fourth quarter and full year ended December 31, 2011 and outlined key objectives and milestones for 2012.

12 Mar 2012

ShangPharma fourth quarter net revenues increase 19.0% to $30.5 million

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2011.

12 Mar 2012